Veeva Systems (VEEV)
(Delayed Data from NYSE)
$221.32 USD
+4.30 (1.98%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $221.37 +0.05 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$221.32 USD
+4.30 (1.98%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $221.37 +0.05 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Zacks News
OPKO Health (OPK) Inks Agreement to Sell Its Ireland Facility
by Zacks Equity Research
OPKO Health (OPK) expects to improve its business efficacy and focus on oral solid dose products post the sale of its Ireland facility.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at Dental segment.
Here's Why You Should Retain Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management.
Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DaVita (DVA) on its slew of tie-ups and strength in its kidney care business.
Cybersecurity Gains Prominence in Healthcare: 3 Stocks to Watch
by Trina Mukherjee
Here we look at three stocks, VEEV, HSIC and BDX, that investors can keep a watch on the back of their robust cybersecurity measures.
AMN Healthcare (AMN) Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
AMN Healthcare (AMN) is optimistic about maintaining its strength in staffing service as well as offering a broad array of services.
Masimo's (MASI) ORi-Guided OLV Procedure Favored by New Study
by Zacks Equity Research
Masimo's (MASI) ORi-guided thoracic anesthesia procedure is likely to reduce hospital stay and increase patient safety.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business. However, intense competition remains a woe.
Patterson Companies' (PDCO) Unit Completes Miller Vet Buyout
by Zacks Equity Research
Patterson Companies' (PDCO) subsidiary completes acquisition of Miller Vet, which is likely to bolster its Animal Health's presence in the companion animal market.
Reasons to Add HealthEquity Stock (HQY) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity (HQY) on its slew of buyouts and strength in HSA.
Dexcom's (DXCM) G6 CGM System Gets Coverage in British Columbia
by Zacks Equity Research
Dexcom's (DXCM) CGM is expected to simplify diabetes management due to increasing access to the life-changing technology.
Ecolab (ECL) to Aid Life Sciences Industry With New Offering
by Zacks Equity Research
Ecolab (ECL) unveils new virtual service offering to help the life sciences industry to address cleaning and disinfection challenges.
Veeva Systems' (VEEV) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Veeva Systems Inc. (VEEV).
Looking for a Growth Stock? 3 Reasons Why Veeva (VEEV) is a Solid Choice
by Zacks Equity Research
Veeva (VEEV) could produce exceptional returns because of its solid growth attributes.
Veeva (VEEV) Customer Intelligence Platform Reaches New Areas
by Zacks Equity Research
Veeva Link's expansion across 11 new therapeutic areas to drive engagement for Veeva's (VEEV) partner companies with key experts.
Why You Should Add Veeva Systems (VEEV) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.
HealthEquity (HQY) Q1 Earnings Beat Estimates, FY22 View Up
by Zacks Equity Research
HealthEquity (HQY) delivers solid growth in HSAs along with recording robust Interchange revenues in the first quarter of fiscal 2022.
BD (BDX) Solidifies Foothold in Healthcare Cybersecurity
by Zacks Equity Research
BD's (BDX) authorization as a CNA is expected to allow it to provide customers with timely information about vulnerabilities in BD products available globally.
Cooper Companies (COO) Q2 Earnings Top Estimates, '21 View Up
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter 2021 earnings reflect solid segmental performance.
Abiomed's (ABMD) preCARDIA Buyout Expands Its Product Portfolio
by Zacks Equity Research
Abiomed's (ABMD) latest acquisition is expected to improve patient outcome as well as lower the cost of care.
Why Veeva (VEEV) Isn't Done Growing Earnings Yet
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Veeva (VEEV).
Strength Seen in Veeva (VEEV): Can Its 10.1% Jump Turn into More Strength?
by Zacks Equity Research
Veeva (VEEV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Veeva Systems (VEEV) Q1 Earnings Beat Estimates, '22 View Up
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal Q1 results reflect impressive performance by both its segments.
Veeva Systems (VEEV) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Veeva (VEEV) delivered earnings and revenue surprises of 16.67% and 5.90%, respectively, for the quarter ended April 2021. Do the numbers hold clues to what lies ahead for the stock?
Veeva Systems' (VEEV) Cloud Offerings Aid Drug Development
by Zacks Equity Research
Veeva Systems' (VEEV) Cloud applications help in simplifying and accelerating drug development on an industry-wide basis.